羟基脲在成人血红蛋白SC病中的真实世界研究:魁北克单中心回顾性队列
该研究在蒙特利尔大学中心医院开展回顾性前后对照队列研究,评估羟基脲对成人HbSC病的疗效与安全性。疗效分析纳入75例、安全性分析纳入110例,羟基脲使血管闭塞危象复合终点年均频率降低56%,血液学不良事件多为轻度,总体耐受良好。
要点
- 羟基脲使成人HbSC病患者血管闭塞危象复合终点年均频率降低56%。
- 血液学不良事件以轻度为主:血小板减少32.7%、中性粒细胞减少23.6%、白细胞减少20.9%。
- 非血液学不良事件最常见为胆红素升高(10.9%),均无症状且无临床肝毒性。
核心结论
- 羟基脲与成人HbSC病患者血管闭塞危象复合终点年均频率的显著降低相关,且总体耐受良好。
研究设计与样本
- 回顾性、单中心、前后对照队列研究,在蒙特利尔大学中心医院开展,患者于2010年1月至2025年7月期间启动羟基脲。
- 共评估263例患者,110例纳入安全性分析,75例纳入疗效分析;疗效分析要求羟基脲使用前随访≥12个月,随访不足者仅纳入安全性分析。
主要发现
- 主要终点为羟基脲使用前12个月至使用后第4-16个月血管闭塞危象复合终点(VOCC:血管闭塞危象、急性胸部综合征、阴茎异常勃起、脾/肝 sequestration)年均频率的变化。
- 羟基脲使平均VOCC降低56%(0.57降至0.25;Δ = -0.32 ± 0.84;95%CI [-0.51, -0.13];p = 0.0015)。
- 血液学不良事件多为轻度:血小板减少32.7%、中性粒细胞减少23.6%、白细胞减少20.9%。
- 非血液学不良事件最常见为胆红素升高(10.9%),均无症状且无临床肝毒性。
临床怎么用
- 对于成人HbSC病患者,羟基脲可考虑用于减少血管闭塞危象复合终点事件,需监测血液学不良事件。
局限性
- 研究为单中心回顾性前后对照设计,疗效分析样本量75例,可能存在选择偏倚和混杂因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Haemoglobin SC (HbSC) disease is the second most prevalent form of sickle cell disease, but evidence for hydroxyurea (hydroxycarbamide; HU) to prevent pain episodes was limited until the prospective identification of variables as outcomes for treatment (PIVOT) trial. To assess HU effectiveness and safety in adults with HbSC, we conducted a retrospective, single-centre, pre-post cohort study at the Centre hospitalier de l'Université de Montréal. Patients initiated HU between January 2010 and July 2025. Effectiveness analysis required ≥12 months of pre-HU follow-up; patients with shorter follow-up were included for the safety analysis only. The primary end-point was the change in the annual frequency of a vaso-occlusive crisis (VOC) composite (VOCC: VOC, acute chest syndrome, priapism, splenic/hepatic sequestration) from 12 months pre-HU to months 4-16 post-HU. Secondary end-points included adverse events (AEs), treatment effectiveness and reasons for HU discontinuation. Of 263 patients assessed, 110 were included in the safety analysis and 75 in the effectiveness analysis. HU reduced mean VOCC by 56% (0.57-0.25; Δ = -0.32 ± 0.84; 95% confidence interval [CI] [-0.51, -0.13]; p = 0.0015). Haematological AEs were mostly mild (thrombocytopenia, 32.7%; neutropenia, 23.6%; leucopenia, 20.9%); bilirubin elevations were the most frequent non-haematological AE (10.9%), all asymptomatic and without clinical hepatotoxicity. In conclusion, HU was associated with a meaningful reduction in VOCC and was generally well tolerated.
引用
- Girard A, Charette L, Haouchine M, et al. Hydroxyurea (hydroxycarbamide) use in adults with haemoglobin SC disease: A real-world study in Quebec. Br J Haematol. 2026. PMID: 42360692. doi:10.1111/bjh.70622
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。